PT  - JOURNAL ARTICLE
AU  - Liu, Tao
AU  - Prescott, Woodruff G.
AU  - Zhou, Xiaobo
TI  - Advances in Non-Type 2 Asthma in the Severe Cases: from molecular insights to novel treatment strategies
AID  - 10.1183/13993003.00826-2023
DP  - 2024 Jan 01
TA  - European Respiratory Journal
PG  - 2300826
4099  - https://publications.ersnet.org//content/early/2024/07/11/13993003.00826-2023.short
4100  - https://publications.ersnet.org//content/early/2024/07/11/13993003.00826-2023.full
AB  - Asthma is a prevalent pulmonary disease that affects nearly 300 million people worldwide and imposes a substantial economic burden. While medication can effectively control symptoms in some patients, severe asthma attacks, driven by airway-inflammation induced by environmental and infectious exposures, continue to be a major cause of asthma-related mortality. Heterogenous phenotypes of asthma include type 2 (T2) and non-T2 asthma. Non-T2 asthma is often observed in patients with severe and/or steroid-resistant asthma. This review will cover the molecular mechanisms, clinical phenotypes, causes and promising treatment of non-T2 severe asthma. Specifically, we will discuss the signaling pathways for non-T2 asthma including the activation of inflammasomes, interferon responses, and IL-17 pathways, and their contributions to the subtypes, progression, and severity of non-T2 asthma. Understanding the molecular mechanisms and genetic determinants underlying non-T2 asthma could form the basis for precision medicine in severe asthma treatment.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of Interest: All authors have nothing to disclose.